| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Departments of Surgery,*
Anatomy,
and
Pathology,§
University of Oulu, Oulu, Finland;
and the Institute of Virology,
Slovak Academy
of Sciences, Bratislava, Slovak Republic
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The novel membrane-associated CA isoenzyme CA IX was initially described as a tumor-associated membrane antigen (MN). Recently, it was reported to contain an extracellular domain with the essential structural features and activity of CAs.8,9 It was originally detected in the human cervical carcinoma cell line HeLa and in a number of human carcinomas but not in the corresponding normal tissues. The expression of MN/CA IX in vitro is positively regulated by the cell density and correlates with the tumorigenic phenotype of hybrids between HeLa and normal human fibroblasts.10 Expression of MN/CA IX in NIH3T3 cells promotes cell proliferation.8 An immunohistochemical study of cervical carcinomas and a polymerase chain reaction-based survey of renal cell carcinomas identified a close association of MN/CA IX expression with these neoplasias and suggested its potential utility as a tumor biomarker.11-13
MN/CA IX has been detected in normal gastric, intestinal, and biliary mucosa.7 Immunohistochemical analysis of the normal large intestine revealed moderate staining in the proximal colon, with the reaction becoming weaker distally. The staining was confined to the basolateral surfaces of the cryptal epithelial cells, the area of greatest proliferative capacity. As MN/CA IX is much more abundant in the proliferating cryptal epithelium than in the upper part of the mucosa, it may play a role in control of the proliferation and differentiation of intestinal epithelial cells.
Cell proliferation increases abnormally in premalignant and malignant lesions of the colorectal epithelium, and therefore it is considered as an indicator of colorectal tumor progression.14,15 A nuclear protein, Ki-67, has been reported as a reliable marker of cell proliferation in the gastrointestinal mucosa.16,17
In the present study, we performed a comparative analysis of MN/CA IX and Ki-67 expression in colorectal tumors. The results allowed us to propose a potential value of MN/CA IX as a marker for cell proliferation in the colorectal mucosa. The increase and abnormal localization of MN/CA IX expression observed in some colorectal tumors suggests that it may be functionally involved in their pathogenesis.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
We studied 69 colonic lesions from 60 patients, including 8 hyperplastic polyps, 1 juvenile polyp, 39 adenomas, and 21 adenocarcinomas. Seven metastases of colorectal adenocarcinomas were also analyzed, including six mesenteric lymph node metastases and one liver metastasis. The adenomatous lesions included 18 tubular, 11 tubulovillous, and 4 villous tumors. The grade of dysplasia was low in 13 lesions, moderate in 19, and high in 8. Some tumors showed varying dysplasia or adenomatous and invasive histology in the same lesion. There were three patients with familial adenomatous polyposis disease from whom two samples were analyzed, one from the cecum and the other from the rectum.
The group of 21 malignant colorectal tumors consisted of 6 well differentiated, 9 moderately differentiated, and 6 poorly differentiated adenocarcinomas. There were 6 adenocarcinomas with a mucinous component. There were 2 carcinomas of stage A in Dukes' classification, 10 at stage B, 7 at stage C, and 2 at stage D. The primary lesions had been isolated from the right colon (n = 13), transverse colon (n = 19), descending colon (n = 8), sigmoid colon (n = 13), and rectum (n = 16).
Preparation of the Samples
The tissue samples were obtained together with routine histopathological specimens taken during colonscopies and surgical operations for colonic tumors carried out at Oulu University Hospital. The study was approved by the Research Ethics Committee of Oulu University Hospital. The samples were fixed with 4% formaldehyde in 0.1 mol/L phosphate-buffered saline and embedded in parafin. Sections of 5 µm were mounted on gelatin-coated microscope slides. Routine histological examination was carried out after hematoxylin and eosin (H&E) staining of the sections.
Antibodies and the Immunostaining Method
The monoclonal antibody M75 recognizing the amino-terminal domain of MN/CA IX protein has been described previously by Pastoreková et al.18 As the secretory isoenzyme CA VI is not expressed in the gut5 but has the greatest homology to MN/CA IX,9 a previously described polyclonal anti-CA VI serum19,20 was used for negative control staining. Additional controls were obtained by omitting the first antibody from immunostaining. Sections were immunostained according to the biotin-streptavidin complex method as described previously.7 The intensity of staining for MN/CA IX was scored by two of the investigators (J. Saarnio and T.J. Karttunen) on a scale of 0 to 2 as follows: 0, absent or weak focal reaction; 1, weak reaction; 2, moderate to strong reaction. The distribution of immunoreactivity between the superficial and deep parts of the mucosa was recorded separately.
To assess proliferative activity, the serial sections were stained with primary antibody to Ki-67 (clone MIB-1, PharMingen, San Diego, CA) and detected by a biotin-streptavidin-peroxidase system, and the sections were counterstained with Harris' hematoxylin. The number of MIB-1-positive cells was counted (by J. Saarnio and T.J. Karttunen) in both the superficial and the deep half of the mucosa. All positively stained nuclei, regardless of intensity, were regarded as positive. An approximation to the Ki-67 score (labeling index) was obtained for each sample as the percentage of tumor cells counted that had positively stained nuclei.
Sixteen samples containing areas of normal mucosa were used to calculate the control labeling index for Ki-67. The mean value of the score for the proliferative zone of the normal mucosa was 37% with a 95% confidence interval from 28% to 46%. To allow comparison with plasma-membrane-associated MN/CA IX, the immunoreactivities of the nuclear Ki-67 were adjusted to the same scale of 0 to 2, on which 0 represents less than 28% (weak staining), 1 represents 28% to 46% (moderate staining), and 2 represents more than 46% (strong staining).
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
. The intensity of MN/CA
IX immunostaining was compared with Ki-67 in the superficial and deep
parts of the lesions. There was a significant correlation between MN/CA
IX and Ki-67 immunoreactivity for superficial (C
= 0.30, P < 0.01) and for cryptal
(C = 0.31, P < 0.01) staining
(Spearman).
|
|
Sixteen samples contained normal mucosa in which MN/CA IX staining was generally quite weak or absent. The staining was localized to the basolateral plasma membrane of the cryptal epithelial cells, and it was also these cells that showed high Ki-67 immunoreactivity. Occasional epithelial cells in the superficial mucosa expressed Ki-67 (mean, 3%), whereas no reaction was detected for MN/CA IX.
Nonneoplastic Polyps of the Large Intestine
The expression of MN/CA IX was studied in one juvenile polyp and
eight hyperplastic polyps. The immunostaining of juvenile polyp for
MN/CA IX was negative. Most hyperplastic polyps showed a weak or
moderate reaction only in the deep parts of the cryptal epithelium
(Figure 1)
, and two of them did not show
any immunoreactivity at all. There were no differences in staining
intensity between the proximal and distal polyps. The cryptal cells
also showed an intense immunoreaction for Ki-67.
|
The 39 adenomatous lesions were obtained from 30 patients,
including 3 with familial adenomatous polyposis disease. No staining
for MN/CA IX was found in eight lesions (20%), which were located
mainly in the distal part of the colon and rectum. Nineteen lesions
(49%) showed weak staining and twelve (31%) a moderate to strong
reaction, located mainly in the basolateral plasma membrane of the
superficial epithelium (Figure 2)
. The
MN/CA-IX-positive lesions were evenly distributed along with the
cranial-caudal axis of the large intestine. No differences in the
immunoreactivity were observed between the adenomas obtained from
patients with familial adenomatous polyposis and sporadic adenomas.
|
The correlations between Ki-67 and MN/CA IX expression in the
superficial and deep parts of the lesions are summarized in Figure 5
.
Both markers show an extension in staining from the crypts to the
surface in adenomatous lesions relative to the normal epithelium.
|
The material included 21 malignant colorectal tumours, 6 well differentiated adenocarcinomas, 9 moderately differentiated, and 6 poorly differentiated. The stage according to Dukes' classification was A in 2 carcinomas, B in 10, C in 7, and D in 2.
No staining for MN/CA IX was observed in 5 carcinomas (24%), whereas 6
(29%) showed a weak positive reaction and 10 (47%) a moderate to
strong reaction. The immunostaining was localized to the plasma
membrane of the tumor cells. Interestingly, the most intense signals
were seen in five of the six adenocarcinomas with a mucinous component
(Figure 3)
. Staining intensity did not
correlate with the location of the carcinoma, but it showed a trend to
correlate with the histological grade, being higher in the well
differentiated tumors. The mean staining intensities were 1.7, 1.2, and
0.8 in grades 1, 2, and 3, respectively (grade 1/grade 3,
P = 0.05, Mann-Whitney). Similarly, the mean staining
intensity was higher (1.5) in less advanced tumors (Dukes A plus B,
n = 12) than in more advanced ones (1.0; Dukes C plus
D, n = 9; P < 0.047, Mann-Whitney
test). The MN/CA IX staining was generally diffuse, being present in
both the superficial and deep parts of the mucosa (Figure 4)
. A diffuse staining pattern was also
characteristic of Ki-67. Interestingly, desmoplastic connective tissue
in the malignant lesions occasionally showed prominent immunostaining
for MN/CA IX (not shown).
|
|
. Both the superficial and deep
parts of the mucosa seem to stain for both antigens more intensely in
malignant tumors than in the normal mucosa, with only a few exceptions.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
MN/CA IX is a transmembrane protein that is widely expressed in the gastrointestinal tract.7 When its full-length cDNA was cloned, this was found to contain a central part with sequence homology to the CAs, on which basis it was thought to participate in the regulation of carbon dioxide homeostasis like the other CAs.8,9 However, this protein has some unique features that suggest a role in intercellular communication or cell proliferation: it shows cell-density-dependent expression in HeLa cells,10 it promotes cell proliferation when transfected into NIH3T3 cells,8 and it is localized to the basolateral membranes of polarized epithelial cells.7 Moreover, expression of MN/CA IX is closely associated with certain human carcinomas.11-13 The purpose of our investigation was to study MN/CA IX expression in colorectal tumors and metastases and to correlate it with the biological behavior of the tumors.
Several important aspects of MN/CA IX expression emerged from this investigation: 1) hyperplastic polyps showed immunoreaction in the cryptal area, as reported earlier in normal mucosa,7 2) MN/CA IX was more widespread and abundant in the surface epithelium of adenomas, 3) the staining pattern was more diffuse in carcinomas than in benign lesions, 4 of all the carcinoma samples, the most prominent reactions were observed in the tumors with a mucinous component, and 5) the desmoplastic connective tissue of some malignant lesions revealed an intense immunoreaction. Furthermore, the results confirmed that MN/CA IX is expressed on the basolateral membranes of enterocytes in hyperplastic polyps and adenomas, whereas it was the polarized expression of MN/CA IX on cell surfaces that was affected in carcinomas.
To demonstrate more precisely the association of MN/CA IX expression with proliferation, we used immunohistochemistry for Ki-67, which is one of the most reliable markers of cell proliferation.17 Ki-67 and MN/CA IX were co-expressed in the same area in these lesions, suggesting that MN/CA IX expression is indeed related to cell proliferation.
In summary, the present results show that the majority of colorectal tumors display abnormal expression of MN/CA IX, suggesting its involvement in their pathogenesis. Furthermore, the co-occurrence of MN/CA IX and Ki-67 at the site of rapid cell proliferation indicates that MN/CA IX could be used as a biomarker of increased cell proliferation in the colorectal mucosa. High expression of MN/CA IX in premalignant lesions such as adenomas suggest that it might be useful in early diagnosis of colorectal tumors.
|
Footnotes |
|---|
Supported by grants from the Sigrid Juselius Foundation to S. Parkkila, from the Maud Kuistila Foundation to A.-K. Parkkila, and from Chiron Diagnostics Corp., Alameda, CA, and the Slovak Scientific Grant Agency to S. Pastorekovà and J. Pastorek.
Accepted for publication April 7, 1998.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
R, Zelnìk V, Saarnio J, Pastorek J: Immunohistochemical demonstration of MN/CA IX, carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 1996, 112:398-408[Medline]
R, Zatòvilovà M, Liao S, Portetelle D, Stanbridge EJ, Zàvada J, Burny A, Kettman R: Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 1994, 9:2877-2888[Medline]
R, Pastorekovà S, Zelník V, Gibadulinovà A, Stanbridge EJ, Zàvada J, Kettman R, Pastorek J: MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 1996, 33:480-487[Medline]
This article has been cited by other articles:
 |
|
 |
|
  A. M. Niemela, P. Hynninen, J.-P. Mecklin, T. Kuopio, A. Kokko, L. Aaltonen, A.-K. Parkkila, S. Pastorekova, J. Pastorek, A. Waheed, et al. Carbonic Anhydrase IX Is Highly Expressed in Hereditary Nonpolyposis Colorectal Cancer Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1760 - 1766. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Brennan, K. Jirstrom, A. Kronblad, R. C. Millikan, G. Landberg, M. J. Duffy, L. Ryden, W. M. Gallagher, and S. L. O'Brien CA IX is an Independent Prognostic Marker in Premenopausal Breast Cancer Patients with One to Three Positive Lymph Nodes and a Putative Marker of Radiation Resistance. Clin. Cancer Res., November 1, 2006; 12(21): 6421 - 6431. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Grosch, T. J. Maier, S. Schiffmann, and G. Geisslinger Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst, June 7, 2006; 98(11): 736 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mayer, M. Hockel, and P. Vaupel Carbonic Anhydrase IX Expression and Tumor Oxygenation Status Do Not Correlate at the Microregional Level in Locally Advanced Cancers of the Uterine Cervix Clin. Cancer Res., October 15, 2005; 11(20): 7220 - 7225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Proescholdt, C. Mayer, M. Kubitza, T. Schubert, S.-Y. Liao, E. J. Stanbridge, S. Ivanov, E. H. Oldfield, A. Brawanski, and M. J. Merrill Expression of hypoxia-inducible carbonic anhydrases in brain tumors Neuro-oncol, October 1, 2005; 7(4): 465 - 475. [Abstract] [PDF]
|
|
|
|
 |
|
 J Chen, C Rocken, J Hoffmann, S Kruger, U Lendeckel, A Rocco, S Pastorekova, P Malfertheiner, and M P A Ebert Expression of carbonic anhydrase 9 at the invasion front of gastric cancers Gut, July 1, 2005; 54(7): 920 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. J. Hoogsteen, H. A.M. Marres, K. I.E.M. Wijffels, P. F.J.W. Rijken, J. P.W. Peters, F. J.A. van den Hoogen, E. Oosterwijk, A. J. van der Kogel, and J. H.A.M. Kaanders Colocalization of Carbonic Anhydrase 9 Expression and Cell Proliferation in Human Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., January 1, 2005; 11(1): 97 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Kim, Z. N. Rabbani, R. T. Vollmer, E.-G. Schreiber, E. Oosterwijk, M. W. Dewhirst, Z. Vujaskovic, and M. J. Kelley Carbonic Anhydrase IX in Early-Stage Non-Small Cell Lung Cancer Clin. Cancer Res., December 1, 2004; 10(23): 7925 - 7933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Maseide, R. A. Kandel, R. S. Bell, C. N. Catton, B. O'Sullivan, J. S. Wunder, M. Pintilie, D. Hedley, and R. P. Hill Carbonic Anhydrase IX as a Marker for Poor Prognosis in Soft Tissue Sarcoma Clin. Cancer Res., July 1, 2004; 10(13): 4464 - 4471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Whittingtons, J. H. Grubb, A. Waheed, G. N. Shah, W. S. Sly, and D. W. Christianson Expression, Assay, and Structure of the Extracellular Domain of Murine Carbonic Anhydrase XIV: IMPLICATIONS FOR SELECTIVE INHIBITION OF MEMBRANE-ASSOCIATED ISOZYMES J. Biol. Chem., February 20, 2004; 279(8): 7223 - 7228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Teye, M. Tsuneoka, N. Arima, Y. Koda, Y. Nakamura, Y. Ueta, K. Shirouzu, and H. Kimura Increased Expression of a Myc Target Gene Mina53 in Human Colon Cancer Am. J. Pathol., January 1, 2004; 164(1): 205 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zisman, A. J. Pantuck, M. H. T. Bui, J. W. Said, R. R. Caliliw, N. Rao, P. Shintaku, F. Berger, S. S. Gambhir, and A. S. Belldegrun LABAZ1: A Metastatic Tumor Model for Renal Cell Carcinoma Expressing the Carbonic Anhydrase Type 9 Tumor Antigen Cancer Res., August 15, 2003; 63(16): 4952 - 4959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E.B. Swinson, J. L. Jones, D. Richardson, C. Wykoff, H. Turley, J. Pastorek, N. Taub, A. L. Harris, and K. J. O'Byrne Carbonic Anhydrase IX Expression, a Novel Surrogate Marker of Tumor Hypoxia, Is Associated With a Poor Prognosis in Non-Small-Cell Lung Cancer J. Clin. Oncol., February 1, 2003; 21(3): 473 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. T. Bui, D. Seligson, K.-r. Han, A. J. Pantuck, F. J. Dorey, Y. Huang, S. Horvath, B. C. Leibovich, S. Chopra, S.-Y. Liao, et al. Carbonic Anhydrase IX Is an Independent Predictor of Survival in Advanced Renal Clear Cell Carcinoma: Implications for Prognosis and Therapy Clin. Cancer Res., February 1, 2003; 9(2): 802 - 811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Leppilampi, P. Koistinen, E.-R. Savolainen, J. Hannuksela, A.-K. Parkkila, O. Niemela, S. Pastorekova, J. Pastorek, A. Waheed, W. S. Sly, et al. The Expression of Carbonic Anhydrase II in Hematological Malignancies Clin. Cancer Res., July 1, 2002; 8(7): 2240 - 2245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Giatromanolaki, M. I. Koukourakis, E. Sivridis, J. Pastorek, C. C. Wykoff, K. C. Gatter, and A. L. Harris Expression of Hypoxia-inducible Carbonic Anhydrase-9 Relates to Angiogenic Pathways and Independently to Poor Outcome in Non-Small Cell Lung Cancer Cancer Res., November 1, 2001; 61(21): 7992 - 7998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Loncaster, A. L. Harris, S. E. Davidson, J. P. Logue, R. D. Hunter, C. C. Wycoff, J. Pastorek, P. J. Ratcliffe, I. J. Stratford, and C. M. L. West Carbonic Anhydrase (CA IX) Expression, a Potential New Intrinsic Marker of Hypoxia: Correlations with Tumor Oxygen Measurements and Prognosis in Locally Advanced Carcinoma of the Cervix Cancer Res., September 1, 2001; 61(17): 6394 - 6399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Chia, C. C. Wykoff, P. H. Watson, C. Han, R. D. Leek, J. Pastorek, K. C. Gatter, P. Ratcliffe, and A. L. Harris Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma J. Clin. Oncol., August 15, 2001; 19(16): 3660 - 3668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Karhumaa, K. Kaunisto, S. Parkkila, A. Waheed, S. Pastorekova, J. Pastorek, W. S. Sly, and H. Rajaniemi Expression of the transmembrane carbonic anhydrases, CA IX and CA XII, in the human male excurrent ducts Mol. Hum. Reprod., July 1, 2001; 7(7): 611 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. P. Beasley, C. C. Wykoff, P. H. Watson, R. Leek, H. Turley, K. Gatter, J. Pastorek, G. J. Cox, P. Ratcliffe, and A. L. Harris Carbonic Anhydrase IX, an Endogenous Hypoxia Marker, Expression in Head and Neck Squamous Cell Carcinoma and its Relationship to Hypoxia, Necrosis, and Microvessel Density Cancer Res., July 1, 2001; 61(13): 5262 - 5267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Wykoff, N. Beasley, P. H. Watson, L. Campo, S. K. Chia, R. English, J. Pastorek, W. S. Sly, P. Ratcliffe, and A. L. Harris Expression of the Hypoxia-Inducible and Tumor-Associated Carbonic Anhydrases in Ductal Carcinoma in Situ of the Breast Am. J. Pathol., March 1, 2001; 158(3): 1011 - 1019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Li, K. Passebosc-Faure, C. Lambert, A. Gentil-Perret, F. Blanc, E. Oosterwijk, J.-F. Mosnier, C. Genin, and J. Tostain The Expression of G250/MN/CA9 Antigen by Flow Cytometry: Its Possible Implication for Detection of Micrometastatic Renal Cancer Cells Clin. Cancer Res., January 1, 2001; 7(1): 89 - 92. [Abstract] [Full Text]
|
|
|
|
|
|
P. Karhumaa, S. Parkkila, A. Waheed, A.-K. Parkkila, K. Kaunisto, P. W. Tucker, C.-J. Huang, W. S. Sly, and H. Rajaniemi Nuclear NonO/p54nrb Protein Is a Nonclassical Carbonic Anhydrase J. Biol. Chem., May 19, 2000; 275(21): 16044 - 16049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Muller-Rover, H. Rossiter, R. Paus, B. Handjiski, E. M. J. Peters, J.-E. Murphy, L. Mecklenburg, and T. S. Kupper Overexpression of Bcl-2 Protects from Ultraviolet B-Induced Apoptosis but Promotes Hair Follicle Regression and Chemotherapy-Induced Alopecia Am. J. Pathol., April 1, 2000; 156(4): 1395 - 1405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kivela, S. Parkkila, J. Saarnio, T. J. Karttunen, J. Kivela, A.-K. Parkkila, A. Waheed, W. S. Sly, J. H. Grubb, G. Shah, et al. Expression of a Novel Transmembrane Carbonic Anhydrase Isozyme XII in Normal Human Gut and Colorectal Tumors Am. J. Pathol., February 1, 2000; 156(2): 577 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. M. Vissers, I. J. M. De Vries, M. W. J. Schreurs, L. P. H. Engelen, E. Oosterwijk, C. G. Figdor, and G. J. Adema The Renal Cell Carcinoma-associated Antigen G250 Encodes a Human Leukocyte Antigen (HLA)-A2.1-restricted Epitope Recognized by Cytotoxic T Lymphocytes Cancer Res., November 1, 1999; 59(21): 5554 - 5559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nogradi The Role of Carbonic Anhydrases in Tumors Am. J. Pathol., July 1, 1998; 153(1): 1 - 4. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Parkkila, H. Rajaniemi, A.-K. Parkkila, J. Kivela, A. Waheed, S. Pastorekova, J. Pastorek, and W. S. Sly Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro PNAS, February 29, 2000; 97(5): 2220 - 2224. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
